Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
LIXTE (NASDAQ:LIXT) signed a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, a leader in deployable, utility-grade battery energy storage systems (BESS). After closing, the company will be renamed NOMAD Power Solutions.
NOMAD is first-to-market with a mobile, utility-grade 1 MW BESS, designed to meet stringent utility performance, safety and interconnection standards. Its mobile architecture can often bypass land-use, environmental reviews and lengthy interconnection queues facing permanent BESS projects.
According to the company, NOMAD’s revenue grew about 175% year-over-year in 2025, with projected 135% growth in 2026. Roughly 75% of sales are inbound, and it is working on more than 30 active utility and infrastructure opportunities across North America.
LIXTE Biotechnology (Nasdaq:LIXT) entered into definitive agreements for a registered direct offering of approximately $16.57 million of common stock and pre-funded warrants, priced at-the-market under Nasdaq rules.
The deal covers 2,625,362 shares and pre-funded warrants, materially strengthening the balance sheet and funding strategic initiatives.
LIXTE (Nasdaq:LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on power for AI and hyperscale data centers. The company plans to seek a strategic acquisition partner for its oncology and med-tech operations and expects to maintain its Nasdaq listing.
Stuart D. Porter, founder of Denham Capital, joins the Board, bringing more than three decades of energy investment experience and oversight of over $12 billion of invested and committed capital.
LIXTE Biotechnology (Nasdaq:LIXT) filed its Form 10-Q for the quarter ended March 31, 2026, and reported progress across its oncology programs.
The company is expanding its ovarian cancer trial of lead compound LB-100 after a study confirmed a favorable safety profile in combination with GSK’s dostarlimab, and presented favorable preliminary clinical results at the 2026 Society of Gynecological Cancer Conference.
LIXTE also advanced integration and strategic initiatives at its recently acquired subsidiary Liora Technologies Europe, supporting growth of the LiGHT System proton therapy platform, while continuing proof-of-concept trials in multiple cancers and maintaining a comprehensive patent portfolio.
LIXT (Nasdaq: LIXT) reported preliminary interim results from a Phase trial combining its proprietary compound LB-100 with dostarlimab in ovarian clear cell carcinoma presented April 13, 2026. All 21 planned patients enrolled; 20 were evaluable for efficacy. At median 12-month follow-up, median OS was not reached; 6-month OS probability was 0.84 and 12-month OS probability was 0.69. Disease Control Rate was 40% (8/20). An additional 21-patient cohort with higher LB-100 exposure is currently enrolling.
LIXTE Biotechnology (Nasdaq: LIXT) filed its 2025 Form 10-K on March 31, 2026, reporting operational progress across clinical, corporate and strategic fronts.
Key highlights: raised >$11 million in two registered direct offerings and a private placement; doubled LB-100 trial enrollment to 42 patients; added Northwestern’s Robert H. Lurie Comprehensive Cancer Center as a new trial site; completed acquisition of UK-based Liora Technologies and its LiGHT System; relocated headquarters to Boca Raton; leadership changes including appointment of Geordan Pursglove as Chairman and CEO.
LIXTE (Nasdaq: LIXT) named Sidney Braun CEO of its Liora Technologies Europe Ltd. subsidiary effective Feb 18, 2026. Braun has more than two decades of healthcare operational and advisory experience and helped create Liora and facilitate LIXTE’s acquisition of Liora assets in November 2025.
Liora develops the proprietary LiGHT System, an electronically controlled proton therapy platform the company says may offer advantages for treating tumors and support a future recurring revenue model for LIXTE.
LIXTE Biotechnology (Nasdaq: LIXT) is the sponsor of the inaugural Good Health: Mind, Body & Soul Summit led by De La Soul on February 19, 2026 at Morehouse College in Atlanta. The invitation-only event convenes health experts, artists, athletes, researchers, and advocates to advance health equity for Black men and families. Programming covers cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness, linking science and lived experience. Attendance is by invitation; more information is available at the summit website.
LIXTE Biotechnology (Nasdaq: LIXT) will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey on January 28-29, 2026. CEO Geordan Pursglove is scheduled to hold one-on-one investor meetings at The Borgata Hotel, Casino & Spa. The company is clinical-stage and advancing LB-100, a PP2A inhibitor. Investors may register or request meetings via the conference registration page.
LIXTE (Nasdaq: LIXT) announced an expansion of its ongoing ovarian clear cell cancer trial combining its compound LB-100 with GSK's dostarlimab. The study, initiated in January 2024, will double enrollment from 21 to 42 patients across two sites: MD Anderson and the Robert H. Lurie Comprehensive Cancer Center at Northwestern. The trial is led by Amir Jazaeri, MD, and Emily M. Hinchcliff, MD, MPH. LIXTE expects initial data from the first 21 patients to be presented in the first half of 2026. The company framed the expansion as progress toward evaluating LB-100’s potential to enhance immunotherapy and chemotherapy outcomes.